[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331583-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331583-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","gi-cancer-mortality-in-participants-in-low-dose-ct-screening-for-lung-cancer-with-a-focus-on-pancreatic-cancer","GI cancer mortality in participants in low dose CT screening for lung cancer with a focus on pancreatic cancer","","Global lung cancer remains the leading cause of cancer mortality, and annual low-dose CT (LDCT) screening is recommended for high-risk individuals. Because these groups also face elevated risk for other cancers, this study evaluates gastrointestinal (GI) cancer deaths in LDCT lung screening participants and examines LDCT’s potential to reveal pancreatic cancer. Using International Early Lung Cancer Action Project (I-ELCAP) data, GI deaths were analyzed in New York State (1992–2010). Radiologists retrospectively reviewed pancreatic cancer within 24 months after baseline LDCT, finding pancreatic cancer as the dominant GI cause and documenting previously undetected pancreatic findings in a substantial fraction of pancreatic cancer deaths.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gi-cancer-mortality-in-participants-in-low-dose-ct-screening-for-lung-cancer-with-a-focus-on-pancreatic-cancer/331583/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gi-cancer-mortality-in-participants-in-low-dose-ct-screening-for-lung-cancer-with-a-focus-on-pancreatic-cancer/331583.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main aim of the study?","Question",{"text":63,"@type":64},"To quantify deaths from gastrointestinal (GI) cancers, with emphasis on pancreatic cancer, among participants in the lung cancer screening program I-ELCAP and to assess whether LDCT can detect pancreatic cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were GI cancer deaths and pancreatic cancer cases identified?",{"text":68,"@type":64},"GI cancer deaths were analyzed using participant data from New York State (1992–2010). Radiologists retrospectively reviewed pancreatic cancer cases occurring within 24 months after baseline LDCT and compared them with original reports.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancer type contributed most to GI cancer mortality, and what did the review find?",{"text":72,"@type":64},"Pancreatic cancer led GI cancer mortality (41.8%), followed by esophageal and colon cancers. Re-reviews identified previously undocumented pancreatic findings in a substantial fraction of participants who died from pancreatic cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331583,1790147224,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nGI cancer mortality in participants in low dose CT screening for lung cancer with a focus on pancreatic cancer  \nLouis Gros, RowenaYip, Yeqing Zhu, Pengfei Li, Natela Paksashvili, Qi Sun, David F. Yankelevitz & Claudia I. Henschke􀀍  \nLung cancer, the leading cause of cancer deaths globally, has better survival rates with early detection. Annual low-dose CT (LDCT) screenings are recommended for high-risk individuals due to age and smoking. These individuals are also at risk for other cancers. Our study explores gastrointestinal  \n(GI) cancer mortality in lung cancer screening participants and the potential of LDCT screenings to detect pancreatic cancer. We utilized data from a prospective multi-institutional cohort study, the International Early Lung Cancer Action Project (I-ELCAP). We analyzed GI cancer deaths among participants in New York State (1992–2010), exploring demographics and GI cancer distribution. Radiologists retrospectively reviewed pancreatic cancer cases within 24 months post-LDCT, comparing findings with original reports. Among 10,150 participants, 189 died from GI cancers; mean age 75, mostly male smokers. Pancreatic cancer (41.8%) led, followed by esophageal (17.5%) and colon cancer (16.9%). Median time between baseline LDCT and death was 116 months (9.7 years) . 82/189 (43.4%) participants died within 5 years of their last LDCT screening, with pancreatic cancer again prominent (45.1%). In 79 pancreatic cancer deaths, 17.7% occurred within 24 months post-LDCT. Are-review identified previously undetected pancreatic findings, with 4 out of 14 participants (28.6%) showing abnormalities. This underscores the potential of lung cancer screening programs to provide insights beyond lung health. This study of over 10,000 participants in a lung cancer screening program reveals that they are at risk for GI cancer deaths, particularly pancreatic cancer. Re-reviews of LDCT scans revealed previously undocumented pancreatic findings in a third of participants who died from pancreatic cancer, underscoring the need to identify, document, and follow up on these findings.  \nKeywords Pancreatic cancer, Early detection, Low-dose CT, Health check  \nLung cancer continues to be the leading cause of cancer-related deaths worldwide, but early detection significantly contributes to lowering lung cancer deaths1. The US Preventive Services Task Force recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history who are currently smoking or have quit within the past 15 years2. Lung cancer screening participants have an increased risk of other cancers due to shared factors like age and smoking3,4.  \nIn the American population, the primary malignant conditions of the gastrointestinal (GI) tract, collectively referred to as GI cancers – including cancers of the esophagus, stomach, small intestines, colon, rectum, anal canal, liver, biliary tract, gallbladder, and pancreas – accounted for more lives lost than respiratory system cancers in 20235. While screening recommendations already exist for colorectal cancers2, gastric cancers in specific populations6, and hepatic cancers in high-risk patients7, there is currently no widely accepted protocol for pancreatic cancer screening, despite it being the third leading cause of cancer-related deaths in the United States. Pancreatic cancer accounts for approximately 62,200 new patients annually, leading to 48,800 deaths8. The most common type, pancreatic ductal adenocarcinoma, constitutes 90% of these cases, with an average diagnosis age of 658. Pancreatic cancer-specific survival rate is low but early-stage diagnosis (stage I) significantly improves five-year survival rates to around 80%9, 10. Pancreatic cancers often develop from well-defined precursor lesions such as pancreatic intraepithelial neoplasms, intraductal papillary ","cbCaisHfNu2BO198","https://ap.wps.com/l/cbCaisHfNu2BO198","pdf",2028109,"English","# Introduction\n## Lung cancer screening and risk of other cancers\n## Lack of established pancreatic screening protocols\n# Methods\n## Data source and study population (I-ELCAP)\n## GI cancer death analysis and pancreatic case review\n# Results\n## GI cancer deaths and leading cancer types\n## Timing from LDCT to death\n## Detection of previously undocumented pancreatic findings\n# Discussion\n## Implications for LDCT screening programs and follow-up","[{\"question\":\"What was the main aim of the study?\",\"answer\":\"To quantify deaths from gastrointestinal (GI) cancers, with emphasis on pancreatic cancer, among participants in the lung cancer screening program I-ELCAP and to assess whether LDCT can detect pancreatic cancer.\"},{\"question\":\"How were GI cancer deaths and pancreatic cancer cases identified?\",\"answer\":\"GI cancer deaths were analyzed using participant data from New York State (1992–2010). Radiologists retrospectively reviewed pancreatic cancer cases occurring within 24 months after baseline LDCT and compared them with original reports.\"},{\"question\":\"Which cancer type contributed most to GI cancer mortality, and what did the review find?\",\"answer\":\"Pancreatic cancer led GI cancer mortality (41.8%), followed by esophageal and colon cancers. Re-reviews identified previously undocumented pancreatic findings in a substantial fraction of participants who died from pancreatic cancer.\"}]","GI cancer mortality in participants in low dose CT screening for lung cancer with a focus on pancreatic cancer | PDF",1789994183,23]